by EpiAxis | Oct 20, 2023 | News
EpiAxis Therapeutics (EpiAxis) is pleased to announce that newly completed research confirms its lead compound epiresatide has a novel mode of action as a first-in-class CoRest Complex Disruptor. Epiresatide has been specifically designed using AI to address the...
by EpiAxis | Sep 6, 2023 | News
EpiAxis CEO Dr Jeremy Chrisp recently presented at Wholesale Investor’s Venture and Capital 2023, an exclusive conference designed to empower high-net-worth VCs, family offices and professional investors with access to investment opportunities and networking....
by EpiAxis | Jul 28, 2023 | News
EpiAxis Therapeutics is delighted to announce its participation in the Venture & Capital Sydney investor conference, scheduled for Thursday, 3 August 2023. The event will be held at Hilton Sydney, located at 488 George St, Sydney NSW, from 9am to 6pm. This...
by EpiAxis | Jul 15, 2023 | News
EpiAxis Therapeutics was thrilled to present at the Wholesale Investor Venture & Capital Europe Conference on 5-6 July 2023. Venture & Capital 2023 was an exclusive conference designed to empower high-net-worth VCs, family offices and professional investors...
by EpiAxis | Jun 22, 2023 | News
EpiAxis Therapeutics is pleased to announce the nomination of epiresatide as its lead candidate for IND advancement. Epiresatide is a generation 2.1 stapled peptide specifically targeting nuclear LSD1, which offers a novel mode of action. Designed to address the...
